Company news
XTL Biopharmaceuticals Ltd. news in 2026
XTL Biopharmaceuticals Ltd.'s news releases, calls and decks from 2026, newest first.
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies
April 29, 2026
XTL Biopharmaceuticals Announces ADS Ratio Change
March 20, 2026
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing
February 27, 2026
XTL Update on Recent Developments
January 29, 2026
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency
January 23, 2026
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
January 13, 2026
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership
January 13, 2026